Skip to main content

Advertisement

Figure 3 | Journal of Translational Medicine

Figure 3

From: Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

Figure 3

De novo production of MRE11 in response to DNA damage. a Cycloheximide (CHM) abolishes MRE11 response to O/C injury. b CHM does not inhibit the expression of γH2AX. 24 and 48 h time points compared to 0 time point, and comparison of O/C treatment only (O/C) to CHM followed by O/C (CHM > O/C) for MRE11 or γH2AX at the same time point.

Back to article page